These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20016017)

  • 1. New therapeutic strategies for raltegravir.
    Garrido C; Soriano V; de Mendoza C
    J Antimicrob Chemother; 2010 Feb; 65(2):218-23. PubMed ID: 20016017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
    Nguyen BY; Isaacs RD; Teppler H; Leavitt RY; Sklar P; Iwamoto M; Wenning LA; Miller MD; Chen J; Kemp R; Xu W; Fromtling RA; Vacca JP; Young SD; Rowley M; Lower MW; Gottesdiener KM; Hazuda DJ
    Ann N Y Acad Sci; 2011 Mar; 1222():83-9. PubMed ID: 21434946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raltegravir: the first HIV type 1 integrase inhibitor.
    Hicks C; Gulick RM
    Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raltegravir: the first in a new class of integrase inhibitors for the treatment of HIV.
    Sayana S; Khanlou H
    Expert Rev Anti Infect Ther; 2008 Aug; 6(4):419-26. PubMed ID: 18662108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy.
    McColl DJ; Chen X
    Antiviral Res; 2010 Jan; 85(1):101-18. PubMed ID: 19925830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.
    Buzón MJ; Marfil S; Puertas MC; Garcia E; Clotet B; Ruiz L; Blanco J; Martinez-Picado J; Cabrera C
    Antivir Ther; 2008; 13(7):881-93. PubMed ID: 19043922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate.
    De Clercq E
    Expert Opin Pharmacother; 2009 Dec; 10(17):2935-7. PubMed ID: 19929712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.
    Malet I; Delelis O; Soulie C; Wirden M; Tchertanov L; Mottaz P; Peytavin G; Katlama C; Mouscadet JF; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2009 Apr; 63(4):795-804. PubMed ID: 19221102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug.
    Wirden M; Simon A; Schneider L; Tubiana R; Malet I; Ait-Mohand H; Peytavin G; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2009 Nov; 64(5):1087-90. PubMed ID: 19717396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raltegravir, an HIV-1 integrase inhibitor for HIV infection.
    Cabrera C
    Curr Opin Investig Drugs; 2008 Aug; 9(8):885-98. PubMed ID: 18666037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line raltegravir. No evidence of comparative effectiveness.
    Prescrire Int; 2010 Nov; 19(110):248-50. PubMed ID: 21284354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Raltegravir as first integrase inhibitor in an HIV-infection].
    Papendorp SG; Brinkman K
    Ned Tijdschr Geneeskd; 2009 Jan; 153(5):166-7. PubMed ID: 19256240
    [No Abstract]   [Full Text] [Related]  

  • 16. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New developments in HIV drug resistance.
    Cane PA
    J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i37-40. PubMed ID: 19675018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
    Baldanti F; Paolucci S; Gulminetti R; Brandolini M; Barbarini G; Maserati R
    J Med Virol; 2010 Jan; 82(1):116-22. PubMed ID: 19950236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of raltegravir-resistant HIV-1 in the central nervous system.
    Watanabe K; Honda M; Watanabe T; Tsukada K; Teruya K; Kikuchi Y; Oka S; Gatanaga H
    Int J STD AIDS; 2010 Dec; 21(12):840-1. PubMed ID: 21297097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.